Detail of the session

Back to list of sessions

Type :
FOCUS SESSION 2

Date :
Thursday 25^th April 2019

Schedule :
16h30 - 18h00

Session Title :

FS02 - Focus Session 2: Advances in Target-Oriented Therapy

O016
16h45 - 17h00

Psoriasis
Brian KIRBY - Ireland

O017
17h00 - 17h15

Psoriatic arthritis
Wolf-Henning BOEHNCKE - Switzerland

O018
17h15 - 17h30

Biomarkers in atopic dermatitis
Emma GUTTMAN-YASSKY - United States

P004
17h30 - 17h35

GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES COMPARED WITH SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE ECLIPSE TRIAL
Kristian REICH - Germany

P005
17h35 - 17h40

LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM MORE THAN 17000 PATIENT-YEARS OF EXPOSURE
Kristian REICH - Germany

P006
17h40 - 17h45

IMMEDIATE ONSET OF ACTION OF BRODALUMAB COMPARED WITH USTEKINUMAB: RESULTS FROM THE PHASE 3 AMAGINE-2 AND -3 STUDIES
Sandra PHILIPP - Germany

P018
17h45 - 17h50

ADALIMUMAB MONOTHERAPY VS. ADALIMUMAB AND METHOTREXATE COMBINATION THERAPY IN PSORIASIS: FIRST-YEAR RESULTS ON DRUG SURVIVAL, EFFECTIVENESS, SAFETY AND IMMUNOGENICITY
Gayle VAN DER KRAAIJ - Netherlands

P019
17h50 - 17h55

A CASE SERIES OF DUPILUMAB IN COMBINATION WITH OTHER BIOLOGIC THERAPIES IN SEVEN PATIENTS
Ana AZUAGA-PINANGO - Spain